📊 IBRX Key Takeaways
Is IBRX a Good Investment? Thesis Analysis
ImmunityBio faces severe financial distress with negative stockholders equity of -$500.5M, indicating technical insolvency. The company burns $304.9M annually in operating cash flow against only $88.3M in cash, providing less than 4 months of runway. Absent significant capital raises or dramatic operational turnaround, the company faces existential liquidity risk.
Why Buy IBRX? Key Strengths
- Maintains $113.3M in annual revenue generation
- Current and quick ratios of 5.1x suggest adequate short-term liquidity on surface
- Biotech sector exposure provides potential for future value creation through successful pipeline programs
IBRX Investment Risks to Consider
- Negative stockholders equity of -$500.5M indicates technical insolvency
- Operating cash burn of -$304.9M with only $88.3M cash = sub-4-month runway
- Operating margin of -226% with no visible profitability trajectory
- Total liabilities ($1.0B) exceed total assets ($501.9M) by significant margin
- Severe dilution or restructuring likely without major financing event
Key Metrics to Watch
- Cash burn rate and cash position (critical for survival)
- Operating cash flow trends and path to cash flow breakeven
- Clinical trial progress and pipeline advancement (potential value creation)
- Capital raise announcements and dilution terms
IBRX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.10x current ratio provides a solid financial cushion.
IBRX Profitability Ratios
IBRX vs Healthcare Sector
How ImmunityBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IBRX Overvalued or Undervalued?
Based on fundamental analysis, ImmunityBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IBRX Balance Sheet & Liquidity
IBRX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: ImmunityBio, Inc.'s revenue has grown significantly by 668% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.15 indicates the company is currently unprofitable.
IBRX Growth Metrics (YoY)
IBRX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.1M | -$67.3M | $-0.07 |
| Q2 2025 | $1.0M | -$92.6M | $-0.10 |
| Q1 2025 | $40.0K | -$129.6M | $-0.15 |
| Q3 2024 | $82.0K | -$85.7M | $-0.14 |
| Q2 2024 | $41.0K | -$134.6M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IBRX Capital Allocation
IBRX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for ImmunityBio, Inc. (CIK: 0001326110)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IBRX
What is the AI rating for IBRX?
ImmunityBio, Inc. (IBRX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IBRX's key strengths?
Claude: Maintains $113.3M in annual revenue generation. Current and quick ratios of 5.1x suggest adequate short-term liquidity on surface.
What are the risks of investing in IBRX?
Claude: Negative stockholders equity of -$500.5M indicates technical insolvency. Operating cash burn of -$304.9M with only $88.3M cash = sub-4-month runway.
What is IBRX's revenue and growth?
ImmunityBio, Inc. reported revenue of $113.3M.
Does IBRX pay dividends?
ImmunityBio, Inc. does not currently pay dividends.
Where can I find IBRX SEC filings?
Official SEC filings for ImmunityBio, Inc. (CIK: 0001326110) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IBRX's EPS?
ImmunityBio, Inc. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IBRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ImmunityBio, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IBRX stock overvalued or undervalued?
Valuation metrics for IBRX: ROE of N/A (sector avg: 15%), net margin of -310.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IBRX stock in 2026?
Our dual AI analysis gives ImmunityBio, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IBRX's free cash flow?
ImmunityBio, Inc.'s operating cash flow is $-304.9M, with capital expenditures of $3.8M. FCF margin is -272.6%.
How does IBRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -310.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 5.10 (avg: 2).